Press Releases Oryzon Genomics S.A.

Equities

ORY

ES0167733015

Delayed BME Other stock markets 11:35:10 2024-04-30 am EDT			5-day change	1st Jan Change
1.96 ^EUR	-2.00%		-1.01%	+3.81%

Apr. 22	Oryzon Genomics, S.A. Secures Another Important Patent for its Lead CNS Asset, Vafidemstat	CI
Apr. 08	ORYZON Announces U.S. FDA Clearance of CTEP-CRADA Phase I/II Clinical Trial Sponsored by NCI for Iadademstat Plus Immune Checkpoint Inhibitors in 1L Extensive Stage Small Cell Lung Cancer	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Oryzon Genomics S A : secures another important patent for its lead CNS asset, vafidemstat	Apr. 22	PU
ORYZON Announces U.S. FDA Clearance of CTEP-CRADA Phase I/II Clinical Trial Sponsored by NCI for Iadademstat Plus Immune Checkpoint Inhibitors in 1L Extensive Stage Small Cell Lung Cancer	Apr. 08	AQ
Oryzon Genomics S A : to provide corporate progress updates at several events in April	Apr. 05	PU
ORYZON Reports Financial Results and Corporate Update for Quarter Ended December 31, 2023	Feb. 26	AQ
ORYZON to Provide Corporate Progress Updates at Several Events in February-March	Feb. 05	AQ
ORYZON to Host KOL Event on Phase IIb PORTICO Topline Study Results of Vafidemstat in Borderline Personality Disorder on January 25, 2024	Jan. 19	AQ
ORYZON Announces Topline Results from Phase IIb PORTICO Study of Vafidemstat in Borderline Personality Disorder (BPD)	Jan. 05	AQ
ORYZON to Provide Corporate Progress Updates at Several Events in January	Jan. 03	AQ
ORYZON Awarded with a Grant for ORY-4001 From the ALS Association in the U.S.	Dec. 04	AQ
ORYZON Announces a New Financing Through a Convertible Bond Program For a Total Amount of Up To €45 Million	Nov. 21	AQ
ORYZON Announces Last Patient Last Visit in its Phase IIb PORTICO Study for Borderline Personality Disorder (BPD)	Nov. 07	AQ
Oryzon Genomics S A : to provide corporate progress updates at several events in November	Nov. 06	PU
ORYZON Reports Financial Results and Corporate Updates for Quarter Ended September 30, 2023	23-10-27	AQ
Oryzon Genomics S A : presents blinded aggregate safety data from vafidemstat’s ongoing Phase IIb PORTICO trial in Borderline Personality Disorder	23-10-10	PU
Oryzon Genomics S A : receives two grants to further explore the role of epigenetic targets in the treatment of neuronal pathologies	23-10-03	PU
Oryzon Genomics S A : to provide corporate progress updates at several events in October	23-10-02	PU
ORYZON to Give Updates on Corporate Progress in September	23-09-05	AQ
Oryzon Genomics S A : announces completed patient recruitment in the PORTICO Phase IIb trial of vafidemstat in Borderline Personality Disorder	23-07-26	PU
Oryzon Genomics S A : reports financial results and corporate updates for half-year ending June 30, 2023	23-07-24	PU
ORYZON Genomics - Positive Aggregate Safety Data From Vafidemstat's Ongoing Phase IIb PORTICO Trial in Borderline Personality Disorder	23-07-06	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Oryzon Genomics S.A.

Equities

ORY

ES0167733015

Press Releases

Filters